A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF Alpha Naive Subjects With Active Radiographic Axial Spondyloarthritis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Ustekinumab (Primary) ; Golimumab
- Indications Ankylosing spondylitis
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 14 Aug 2017 Planned End Date changed from 17 Jun 2019 to 6 Sep 2019.
- 22 Jul 2017 Trial has been completed in Poland. (end date: 2017-05-17).
- 13 Jun 2017 Status changed from recruiting to active, no longer recruiting.